Literature DB >> 7685318

Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis.

Y Hinoda1, N Nakagawa, H Nakamura, Y Makiguchi, F Itoh, M Adachi, T Yabana, K Imai, A Yachi.   

Abstract

This study aims at clarifying whether the humoral immune response to the tandem repeat domain of MUC1 can be induced or not in vivo. The expression of MUC1 mRNA in the colon was revealed by Northern blot analysis, and cDNA cloning of an extracellular tandemly repeated domain of MUC1 was then performed to prepare the recombinant MUC1 protein. A cDNA clone coding for ten repeat domains was ligated into an expression vector in prokaryotes, resulting in a recombinant protein which could react with the MAb MUSE11 against an adenocarcinoma-associated antigen whose epitope has been shown to be localized in the tandem repeat domain on MUC1. The reactivity of sera from patients with ulcerative colitis with the recombinant protein was evaluated by SDS-PAGE and Western blot analysis to detect the antibodies against this tandem repeat domain. Five out of 19 serum samples tested positive, and these reactions were totally inhibited by MAb MUSE11, suggesting that the epitope recognized by these antibodies in sera is almost identical to that recognized by MAb MUSE11. The data represent the first demonstration of antibody production against a peptide epitope of the tandem repeat domain of MUC1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685318     DOI: 10.1016/0165-2478(93)90086-h

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  10 in total

1.  Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.

Authors:  Yan Tang; Li Wang; Peiyin Zhang; Hongfei Wei; Rui Gao; Xinming Liu; Yongli Yu; Liying Wang
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

Review 2.  The epidemiology of endometrial and ovarian cancer.

Authors:  Daniel W Cramer
Journal:  Hematol Oncol Clin North Am       Date:  2011-11-25       Impact factor: 3.722

3.  Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis.

Authors:  Rob J Longman; Richard Poulsom; Anthony P Corfield; Bryan F Warren; Nicholas A Wright; Michael G Thomas
Journal:  J Histochem Cytochem       Date:  2006-08-21       Impact factor: 2.479

Review 4.  MUC1 in endometriosis and ovarian cancer.

Authors:  Anda M Vlad; Iulia Diaconu; Kira R Gantt
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  CA125 immune complexes in ovarian cancer patients with low CA125 concentrations.

Authors:  Daniel W Cramer; Dennis J O'Rourke; Allison F Vitonis; Ursula A Matulonis; Daniel A Dijohnson; Patrick M Sluss; Christopher P Crum; Brian C-S Liu
Journal:  Clin Chem       Date:  2010-10-13       Impact factor: 8.327

6.  Immune Responses to the MUC1 Mucin.

Authors:  Graeme Denton; Michael R Price
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

Review 7.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

8.  Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients.

Authors:  M M Gourevitch; S von Mensdorff-Pouilly; S V Litvinov; P Kenemans; G J van Kamp; A A Verstraeten; J Hilgers
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

9.  Natural and Induced Humoral Responses to MUC1.

Authors:  Silvia Von Mensdorff-Pouilly; Maria Moreno; René H M Verheijen
Journal:  Cancers (Basel)       Date:  2011-07-29       Impact factor: 6.639

10.  Expression of sulfated carbohydrate chains detected by monoclonal antibody 91.9H in human gastric cancer tissues.

Authors:  Y Ohe; Y Hinoda; T Irimura; K Imai; A Yachi
Journal:  Jpn J Cancer Res       Date:  1994-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.